ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION
Clinical trials for ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat leukemia in early trial
Disease control Recruiting nowThis early-phase study tests whether combining two targeted drugs, SNDX-5613 and gilteritinib, is safe and effective for adults with a specific type of acute myeloid leukemia (AML) that has returned or not responded to treatment. The cancer must have a FLT3 mutation plus either a…
Matched conditions: ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION
Phase: PHASE1 • Sponsor: Uma Borate • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New drug combo targets leukemia that Won't quit
Disease control Recruiting nowThis early-stage study tests a combination of two drugs, Vyxeos and Gilteritinib, for adults with a specific genetic form of acute myeloid leukemia (FLT3-mutated) that has returned or not responded to prior treatment. The goal is to find the safest dose and see how well it contro…
Matched conditions: ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC
-
Heart check for leukemia pill: healthy volunteers wanted
Knowledge-focused Recruiting nowThis study checks whether a single dose of XY0206, a drug being developed for a type of leukemia, changes the heart's electrical activity (QTc interval) in healthy adults. About 45 to 75 healthy Chinese volunteers aged 18-45 will take one dose of the drug, a placebo, or a control…
Matched conditions: ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION
Phase: PHASE1 • Sponsor: Shijiazhuang Yiling Pharmaceutical Co. Ltd • Aim: Knowledge-focused
Last updated May 17, 2026 07:04 UTC